Login
PLIANT THERAPEUTICS, INC. logo

PLIANT THERAPEUTICS, INC.

pliantrx.com

What Do They Do?

Develops integrin-based drug candidates for people with solid tumors and builds a platform for delivering medicines to specific tissues.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +7% (Loss)
vs −$26.3M in Q3 FY2025
  • Mar 27, 2026 Opened an at-the-market stock offering program for up to $50.0 million. The company also terminated its prior sales agreement; it had not sold shares under that agreement.

From fibrosis to oncology The earlier report centered the business on fibrosis candidates for lung and liver disease, including bexotegrast. The latest report centers its lead program on a solid-tumor candidate and describes drug delivery and a broader integrin platform.

Who Do They Compete With?

Competes with AbbVie, Bicara Therapeutics, CatalyM, Corbus Pharmaceuticals, Incyte, IO Biotech, Keros Therapeutics, Oncotelic Therapeutics, Pfizer, Roche/Genetech, Scholar Rock, and Sirnaomics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support